Respiratory nurse lead Carol Stonham outlines what nurses in primary care need to know about changes in the diagnosis and ...

Part two of this series sees Ravijyot Saggu explore pharmacological management recommendations from the new joint chronic ...

Ravijyot Saggu explores key updates and implications of the new joint chronic asthma guidelines for diagnosis and monitoring.

Over the last 10 years, the long-acting beta-agonists (LABAs) have become an important add-on therapy for the management of asthma, and they are now often used with ICS in a single ICS/LABA ...

Background: Current guidelines recommend the use of inhaled corticosteroids (ICSs) added to long-acting β 2-agonists (LABAs ... of LABAs/ICSs compared with LABA monotherapy for patients with ...

What is the clinical and cost-effectiveness of regular 'fixed-dose' inhaled corticosteroid (ICS) regimens (using SABA [short-acting beta2 agonist] as a reliever) compared with 'as-needed' strategies ...

b p represents the level of significance for the comparison between patients who filled an initial prescription for a long-acting β 2-adrenergic agonist ... starting an LABA 6,043 (60.4) 760 ...